Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Michael A Zielinski"'
Autor:
Eric L. Simpson, Gil Yosipovitch, Andrew G. Bushmakin, Joseph C. Cappelleri, Thomas Luger, Sonja Ständer, Wynnis L. Tom, William C. Ports, Michael A. Zielinski, Anna M. Tallman, Huaming Tan, Robert A. Gerber
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 9, Pp 756-761 (2019)
Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship am
Externí odkaz:
https://doaj.org/article/e2d64085c0c24480a5e91c42823e54ba
Autor:
Zoe D. Draelos, Steven R. Feldman, Brian Berman, Melissa Olivadoti, Debra Sierka, Anna M. Tallman, Michael A. Zielinski, William C. Ports, Sheryl Baldwin
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 1, Pp 71-102 (2019)
Abstract Atopic dermatitis (AD) is a common inflammatory skin disease that is accompanied by increased sensitivity to itch-provoking and pain-provoking stimuli. Patients with AD experience skin pain before initiation of therapy and have also reported
Externí odkaz:
https://doaj.org/article/5537feaa51964b89a4edb63ba45b156e
Autor:
Jonathan I. Silverberg, Anna M. Tallman, William C. Ports, Robert A. Gerber, Huaming Tan, Michael A. Zielinski
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 13, p adv00170 (2020)
Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis pools results from 2 phase 3 studies (ClinicalTrials.gov, NCT02118766 [AD-301]; NCT02118792 [AD-
Externí odkaz:
https://doaj.org/article/aaadd477b474454f946fd82746e88b94
Autor:
Sonja Ständer, Thomas Luger, Joseph C. Cappelleri, Andrew G. Bushmakin, Carla Mamolo, Michael A. Zielinski, Anna M Tallman, Gil Yosipovitch
Publikováno v:
Acta Dermato-Venereologica, Vol 98, Iss 3, Pp 340-345 (2017)
Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasi
Externí odkaz:
https://doaj.org/article/889b88b215124bb092180771b974ddd0
Autor:
Thomas A. Luger, Adelaide A. Hebert, Andrea L. Zaenglein, Jonathan I. Silverberg, Huaming Tan, William C. Ports, Michael A. Zielinski
Publikováno v:
Pediatric Drugs. 24:175-183
This post hoc analysis of pooled data from two phase III studies (AD-301: NCT02118766; AD-302: NCT02118792) explored the efficacy and safety of crisaborole ointment, 2%, a nonsteroidal phosphodiesterase 4 inhibitor, for the treatment of mild-to-moder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c75997b98dbfd0a3758370eef50adba
https://doi.org/10.1007/s40272-021-00490-y
https://doi.org/10.1007/s40272-021-00490-y
Autor:
Claire Ervin, Joshua A. Zeichner, Rebecca Crawford, Emily Evans, Marco DiBonaventura, Michael A. Zielinski, Steven R. Feldman, Daniela E. Myers, Liza Takiya, Joseph C. Cappelleri
Publikováno v:
Journal of Dermatological Treatment. 33:2225-2233
Background The expanding number of potential treatment options for atopic dermatitis (AD) highlights the need to better understand the treatment preferences of individuals with AD. Objective This study identified attributes that most greatly influenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159964d42ff6386738809a529ff2a032
https://doi.org/10.1080/09546634.2021.1940810
https://doi.org/10.1080/09546634.2021.1940810
Autor:
Anna M. Tallman, Chuanbo Zang, Kim A. Papp, Jonathan I. Silverberg, William C. Ports, Thomas A. Luger, Debra Sierka, Michael A. Zielinski, Lawrence F. Eichenfield
Publikováno v:
Journal of Drugs in Dermatology. 19:50-64
Approval of the new topical phosphodiesterase 4 inhibitor crisaborole ointment, 2%, to treat mild-to-moderate atopic dermatitis (AD) warrants careful consideration of available efficacy and safety data for topical therapies to contribute to a better
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddad179e16d7c3402fc0cd34583f5027
https://doi.org/10.36849/jdd.2020.4508
https://doi.org/10.36849/jdd.2020.4508
Autor:
Yeriel Estrada, Etienne Saint-Cyr Proulx, Ana B. Pavel, William C. Ports, John L. Werth, Aisleen Diaz, Ivana Vranic, Bonnie Vlahos, Vivek S. Purohit, Robert Bissonnette, Chuanbo Zang, Emma Guttman-Yassky, Michael A. Zielinski
Publikováno v:
Journal of Allergy and Clinical Immunology. 144:1274-1289
Background Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action of crisaborole and its effects on lesional measures of disease severity are not y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648e0a08b6c1110c5461bed1188f5893
https://doi.org/10.1016/j.jaci.2019.06.047
https://doi.org/10.1016/j.jaci.2019.06.047
Autor:
Wynnis L. Tom, Andrew G. Bushmakin, Eric L. Simpson, Thomas A. Luger, Joseph C. Cappelleri, Anna M. Tallman, Sonja Ständer, Huaming Tan, William C. Ports, Gil Yosipovitch, Michael A. Zielinski, Robert A. Gerber
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 9, Pp 756-761 (2019)
Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d110f2f4fe79d7d66445fed73f24017b
https://doaj.org/article/e2d64085c0c24480a5e91c42823e54ba
https://doaj.org/article/e2d64085c0c24480a5e91c42823e54ba
Autor:
Brian Berman, Zoe Diana Draelos, Melissa Olivadoti, Anna M. Tallman, William C. Ports, Sheryl Baldwin, Steven R. Feldman, Debra Sierka, Michael A. Zielinski
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 1, Pp 71-102 (2019)
Dermatology and Therapy
Dermatology and Therapy
Atopic dermatitis (AD) is a common inflammatory skin disease that is accompanied by increased sensitivity to itch-provoking and pain-provoking stimuli. Patients with AD experience skin pain before initiation of therapy and have also reported painful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251b59409e0cf19dbec260f4a7e3bbb0
http://link.springer.com/article/10.1007/s13555-019-0280-7
http://link.springer.com/article/10.1007/s13555-019-0280-7